NASDAQ · ATRA
Atara Biotherapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ATRA: Nov 11, 2026
Atara Biotherapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.32.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · Zacks · Fintel- RTTNews · Oct 2, 2:50 PM EDTBiotech Stocks Move Higher – NIVF +25%, ICU +23%, ATRA +11%, INDP +9%(RTTNews) – Several biotech and healthcare stocks moved sharply higher, driven by company-specific developments including financing activity, regulatory updates and strategic initiatives.
- RTTNews · Sep 30, 8:52 AM EDTAtara Resubmits Tabelecleucel BLA To FDA(RTTNews) – On Wednesday, Atara Biotherapeutics (ATRA) said its partner, Pierre Fabre Pharmaceuticals, has resubmitted the Biologics License Application (BLA) for tabelecleucel to the U.S. Food and Drug Administration (FDA).
- RTTNews · Sep 8, 2:43 PM EDT5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara(RTTNews) – Several biotech stocks were in focus Tuesday, including Bluejay Diagnostics following a federal healthcare partnership with Lovell Government Services; Pharvaris after positive Phase 3 CHAPTER-3 results; Roivant following positive Phase 2 PHocus data; PDS Biotech afte
- BNK Invest · Sep 8, 10:49 AM EDTTuesday 9/8 Insider Buying Report: UBER, ATRABargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we
- RTTNews · Sep 8, 12:11 AM EDTISpecimen In Focus, Genelux Nears Phase 3 Ovarian Cancer Data, Biofrontera Awaits FDA Decision(RTTNews) – The biotech and pharma stocks to watch on Tuesday include iSpecimen, which gained more than 37% in overnight trading on Monday despite no specific news; Genelux, with a key clinical catalyst for its lead candidate Olvi-Vec expected in the coming months; Anixa Bioscien
- RTTNews · Jun 30, 1:25 AM EDTTenaya Therapeutics Names Eric Hyllengren CFO Ahead Of Higa Retirement(RTTNews) – Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company, announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, following the planned retirement of Hiro Higa, Senior Vice President of Finance, in the third qu
- RTTNews · Jun 15, 5:31 AM EDTAtara Announces Departure Of Carol Gallagher As Director, Brian Cherry To Succeed(RTTNews) – Atara Biotherapeutics, Inc. (ATRA), a clinical-stage biotechnology company, announced the departure of Carol Gallagher from its Board of Directors and appointed Brian Cherry to succeed her.
- Zacks · May 21, 10:37 AM EDTATRA Stock Shoots Up 82% in a Month: Here's What You Should KnowAtara stock soars 82% as the FDA outlines a regulatory pathway for its lead product candidate, tab-cel, reviving hopes for potential U.S. approval, after two prior CRLs.
- Fintel · May 18, 8:03 PM EDTFreedom Broker Upgrades Atara Biotherapeutics (ATRA)Fintel reports that on May 18, 2026, Freedom Broker upgraded their outlook for Atara Biotherapeutics (NasdaqGS:ATRA) from Sell to Hold. Analyst Price Forecast Suggests 29.49% Upside
- Fintel · May 14, 11:08 AM EDTAtara Biotherapeutics (ATRA) Price Target Increased by 25.00% to 11.90The average one-year price target for Atara Biotherapeutics (NasdaqGS:ATRA) has been revised to $11.90 / share. This is an increase of 25.00% from the prior estimate of $9.52 dated April 25, 2026. The price target is an average of many targets provided by anal
- Fintel · May 8, 8:05 PM EDTCanaccord Genuity Upgrades Atara Biotherapeutics (ATRA)Fintel reports that on May 8, 2026, Canaccord Genuity upgraded their outlook for Atara Biotherapeutics (NasdaqGS:ATRA) from Hold to Buy. Analyst Price Forecast Suggests 13.88% Upside
- RTTNews · May 8, 8:17 AM EDTWeekly Buzz:FDA Clears Tab-cel Path, Arvinas Wins PROTAC Nod, Novartis Cuts Jobs, Roche Buys PathAI(RTTNews) – This week's biotech roundup features the FDA's path forward for Atara's tab-cel, Arvinas' first-in-class PROTAC approval, and Incyte's Jakafi XR securing a regulatory nod. The week also saw Novartis announcing a site closure, Roche striking a $750 million PathAI deal,
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Atara Biotherapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.